Patents by Inventor Tomasz STRYJEWSKI

Tomasz STRYJEWSKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOTREXATE TREATMENT METHODS
    Publication number: 20240197740
    Abstract: The present disclosure provides compositions of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), uveitis, macular edema, and uveitic macular edema.
    Type: Application
    Filed: December 20, 2023
    Publication date: June 20, 2024
    Inventors: Stephen Gitu MACHATHA, Dean Eliott, Tomasz Stryjewski
  • Ophthalmic formulations of methotrexate
    Patent number: 12005060
    Abstract: The present disclosure provides formulations of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), intraocular lymphoma (e.g., PVRL), and intraocular inflammation.
    Type: Grant
    Filed: September 15, 2022
    Date of Patent: June 11, 2024
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Dean Eliott, Stephen Gitu Machatha, Pramod Sarpotdar, Tomasz Stryjewski
  • Ophthalmic formulations of methotrexate
    Patent number: 12005061
    Abstract: The present disclosure provides formulations of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), intraocular lymphoma (e.g., PVRL), and intraocular inflammation.
    Type: Grant
    Filed: September 15, 2022
    Date of Patent: June 11, 2024
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Dean Eliott, Pramod Sarpotdar, Stephen Gitu Machatha, Tomasz Stryjewski
  • Methotrexate treatment methods
    Patent number: 11911385
    Abstract: The present disclosure provides compositions of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), uveitis, macular edema, and uveitic macular edema.
    Type: Grant
    Filed: December 14, 2022
    Date of Patent: February 27, 2024
    Assignee: ALDEYRA THERAPEUTICS, INC.
    Inventors: Stephen Gitu Machatha, Dean Eliott, Tomasz Stryjewski
  • OPHTHALMIC FORMULATIONS OF METHOTREXATE
    Publication number: 20230017743
    Abstract: The present disclosure provides formulations of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), intraocular lymphoma (e.g., PVRL), and intraocular inflammation.
    Type: Application
    Filed: September 15, 2022
    Publication date: January 19, 2023
    Inventors: Dean ELIOTT, Stephen Gitu MACHATHA, Pramod SARPOTDAR, Tomasz STRYJEWSKI
  • OPHTHALMIC FORMULATIONS OF METHOTREXATE
    Publication number: 20230018197
    Abstract: The present disclosure provides formulations of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), intraocular lymphoma (e.g., PVRL), and intraocular inflammation.
    Type: Application
    Filed: September 15, 2022
    Publication date: January 19, 2023
    Inventors: Dean ELIOTT, Stephen Gitu MACHATHA, Pramod SARPOTDAR, Tomasz STRYJEWSKI
  • OPHTHALMIC FORMULATIONS OF METHOTREXATE
    Publication number: 20220370460
    Abstract: The present disclosure provides formulations of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), intraocular lymphoma (e.g., PVRL), and intraocular inflammation.
    Type: Application
    Filed: September 11, 2020
    Publication date: November 24, 2022
    Inventors: Dean ELIOTT, Stephen Gitu MACHATHA, Pramod SARPOTDAR, Tomasz STRYJEWSKI